Comparison of stepwise addition of prandial insulin to a basal-bolus regimen when basal insulin is insufficient for glycaemic control in type 2 diabetes: Results of the OSIRIS study

被引:16
作者
Raccah, D. [1 ]
Haak, T. J. [2 ]
Huet, D. [3 ]
Monnier, L. [4 ]
Robertson, D. [5 ]
Labard, P. [6 ]
Soler, J. [7 ]
Penfornis, A. [8 ]
机构
[1] Univ Hosp St Marguerite, Dept Diabetol, F-13009 Marseille, France
[2] Diabet Zentrum, D-97980 Bad Mergentheim, Germany
[3] Ctr Hosp St Joseph, F-75014 Paris, France
[4] Hop Lapeyronie, F-34295 Montpellier, France
[5] Sandwell Gen Hosp, Sandwell Med Res Unit, W Bromwich B71 4HJ, England
[6] Sanofi, F-75008 Paris, France
[7] Ciutat Sanitaria & Univ Bellvitge, Dept Endocrinol, Barcelona, Spain
[8] Univ Franche Comte, CHU Jean Minjoz, F-25000 Besancon, France
关键词
Type; 2; diabetes; Basal-bolus; Prandial insulin; Insulin glargine; Insulin glulisine; Randomised trial; BLOOD-GLUCOSE; ONE INJECTION; THERAPY; MANAGEMENT; GLULISINE; HYPERGLYCEMIA; GLARGINE; EFFICACY; MELLITUS; TELECARE;
D O I
10.1016/j.diabet.2012.08.010
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aim. - The metabolic efficacy of adding prandial insulin in a stepwise manner to a straightforward basal-bolus regimen was compared in patients with type 2 diabetes mellitus (T2DM), suboptimally controlled by oral antidiabetic drugs (OADs) and once-daily basal insulin. Methods. - In this international randomized, parallel-group, non-inferiority study, 811 patients with poorly controlled type 2 diabetes using basal insulin were switched to insulin glargine (GLAR) for 6 months while continuing OADs. Patients with HbA(1c) > 7% and FPG < 120 mg/dL (n = 476) were then randomized to either group 1, GLAR + metformin (MET) + 3 x insulin glulisine (GLU), group 2, GLAR + MET + 1-3 x GLU, or group 3, GLAR + MET + insulin secretagogue (IS) + 1-3 x GLU, for 12 months. Objectives were to show the non-inferiority of efficacy of group 2 vs group 1 and vs group 3. Non-inferiority of group 2 vs group 1 was concluded if the upper limit of the 95% confidence interval (CI) for the HbA(1c) difference was <= to 0.4%. Results. - The adjusted HbA(1c) difference of group 2 vs 1 for the per-protocol population crossed the non-inferiority margin (0.228, 95% CI: -0.018-0.473). There was significantly less weight gain in group 2 compared with group 1, but adverse events were otherwise similar between the two groups. In patients with HbA(1c) < 8% at baseline, non-inferiority was achieved in group 2 vs group 1. Conclusion. - Although non-inferiority was not achieved, stepwise intensification of GLU added to GLAR showed efficacy close to that of the basal-bolus approach and with significantly less weight gain. (C) 2012 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:507 / 514
页数:8
相关论文
共 21 条
[1]  
[Anonymous], DIABETOLOGIA S1
[2]   The importance of first-phase insulin secretion: implications for the therapy of type 2 diabetes mellitus [J].
Del Prato, S ;
Tiengo, A .
DIABETES-METABOLISM RESEARCH AND REVIEWS, 2001, 17 (03) :164-174
[3]   Telecare Provides Comparable Efficacy to Conventional Self-Monitored Blood Glucose in Patients with Type 2 Diabetes Titrating One Injection of Insulin Glulisine-the ELEONOR Study [J].
Del Prato, Stefano ;
Nicolucci, Antonio ;
Lovagnini-Scher, Augusto C. ;
Turco, Salvatore ;
Leotta, Sergio ;
Vespasiani, Giacomo .
DIABETES TECHNOLOGY & THERAPEUTICS, 2012, 14 (02) :175-182
[4]   Psychosocial therapies in diabetes - Report of the psychosocial therapies working group [J].
Delamater, AM ;
Jacobson, AM ;
Anderson, B ;
Cox, D ;
Fisher, L ;
Lustman, P ;
Rubin, R ;
Wysocki, T .
DIABETES CARE, 2001, 24 (07) :1286-1292
[5]   Outpatient insulin therapy in type 1 and type 2 diabetes mellitus - Scientific review [J].
DeWitt, DE ;
Hirsch, IB .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 289 (17) :2254-2264
[6]   Premixed insulin analogues for the treatment of diabetes mellitus [J].
Garber, AJ .
DRUGS, 2006, 66 (01) :31-49
[7]   Relationship between patient medication adherence and subsequent clinical inertia in type 2 diabetes glycemic management [J].
Grant, Richard ;
Adams, Alyce S. ;
Trinacty, Connie Mah ;
Zhang, Fang ;
Kleinman, Ken ;
Soumerai, Stephen B. ;
Meigs, James B. ;
Ross-Degnan, Dennis .
DIABETES CARE, 2007, 30 (04) :807-812
[8]   Insulin treatment for type 2 diabetes: When to start, which to use [J].
Hamaty, Marwan .
CLEVELAND CLINIC JOURNAL OF MEDICINE, 2011, 78 (05) :332-342
[9]   Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes [J].
Holman, Rury R. ;
Thorne, Kerensa I. ;
Farmer, Andrew J. ;
Davies, Melanie J. ;
Keenan, Joanne F. ;
Paul, Sanjoy ;
Levy, Jonathan C. .
NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (17) :1716-1730
[10]   Prandial premixed insulin analogue regimens versus basal insulin analogue regimens in the management of type 2 diabetes: An evidence-based comparison [J].
Ilag, Liza L. ;
Kerr, Lisa ;
Malone, James K. ;
Tan, Meng H. .
CLINICAL THERAPEUTICS, 2007, 29 :1254-1270